{"entity":{"id":"d-0502","kind":"drug","name":"D-0502","aka":[],"tldr":"D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","summary":"D-0502 is a small-molecule drug developed by InventisBio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial. ClinicalTrials.gov describes the intervention as: * Dosage form: Tablet * Administration route: Oral, once a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT06954961, plans to enrol 640 participants with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of D-0502","url":"https://clinicaltrials.gov/search?intr=D-0502"},{"label":"Sponsor pipeline page","url":"https://www.inventisbio.com/en/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["inventisbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06954961"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/d-0502/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/"}],"trial":[{"id":"nct06954961","kind":"trial","name":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct06954961/"}]}}